1300031-82-6

Basic information

• Product Name: N-(6-BROMO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-4-YL)FORMAMIDE
• Synonyms: N-(6-BROMO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-4-YL)FORMAMIDE
• CAS NO: 1300031-82-6
• Molecular Formula: C11H13BrN2O
• Molecular Weight: 269.13772
• Mol File: 1300031-82-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(6-BROMO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-4-YL)FORMAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-BROMO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-4-YL)FORMAMIDE(1300031-82-6)
• EPA Substance Registry System: N-(6-BROMO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-4-YL)FORMAMIDE(1300031-82-6)

Safety Data

• Hazardous Substances Data: 1300031-82-6(Hazardous Substances Data)

Upstream product

• 106-40-1 4-bromo-aniline 
• 13162-05-5 n-vinylformamide 
• 1300031-83-7 N-(1-(1H-benzo[d][1,2,3]triazol-1-yl)ethyl)-4-bromoaniline 

Downstream Products

• 1300031-52-0 4-((2S,4R)-1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid 
• 1300031-70-2 methyl 4-{(2S,4R)-1-acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1,2,3,4-tetrahydro-6-quinolinyl}benzoate 
• 1300691-55-7 4-((2S,4R)-1-acetyl-2-methyl-4-(p-tolylamino)-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid 

Relevant articles and documents

NOVEL PROCESS

A compound or a pharmaceutically acceptable salt or solvate thereof with a molecular weight in the range 100 to 750 which inhibits the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner which is able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at and c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5A range of any of the heavy atoms of the following bromodomain residues which define the binding pocket: for use in the treatment of chronic autoimmune and inflammatory conditions, acute inflammatory conditions or cancer.

Tetrahydroquinoline Derivatives And Their Pharmaceutical Use

Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE

Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.